EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.
“Understanding whether [therapeutic drug monitoring (TDM)] would improve ownership of patient health decisions is important,” Charlotte L.M. Krieckaert, MD, of the Amsterdam Rheumatology and Immunology Center, and co-authors wrote in the Annals of the Rheumatic Diseases. “Equally, many rheumatologists are unaware of the pharmacokinetic properties of biopharmaceuticals and

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.
“Understanding whether [therapeutic drug monitoring (TDM)] would improve ownership of patient health decisions is important,” Charlotte L.M. Krieckaert, MD, of the Amsterdam Rheumatology and Immunology Center, and co-authors wrote in the Annals of the Rheumatic Diseases. “Equally, many rheumatologists are unaware of the pharmacokinetic properties of biopharmaceuticals and